Results 41 to 50 of about 229,492 (119)
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj +1 more source
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou +7 more
wiley +1 more source
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Evaluation of clinical features and risk factors in juvenile Graves' ophthalmopathy [PDF]
[...]. Aim and objectives. The aim of the present study was to evaluate the features of juvenile Graves' ophthalmopathy and identify the risk factors that may influence the development of the disease. The objectives of the study were as follows: 1.
Jarušaitienė, Dalia
core
Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik +4 more
doaj +1 more source
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng +8 more
doaj +1 more source
Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset +13 more
wiley +1 more source
The Influence of Prior Hyperthyroidism on Euthyroid Graves’ Ophthalmopathy [PDF]
Background. To investigate the influence of previous exposure to elevated thyroid hormones in euthyroid Graves' ophthalmopathy. Design. Retrospective, observational case series in university setting Median follow-up of 1 year with ranges of 0,8-7,6 years.
Ilse Mombaerts +5 more
core +1 more source
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source
A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta +17 more
doaj +1 more source

